




Supplemental Figure 1. c-Maf ATAM and c-Maf $^{flox/flox}$ mice showed comparable pancreas, liver, small intestine and kidney function and structure, but decreased albumin reabsorption in the proximal tubules and excess basic amino acid excretion. (A) IRSI and (B) IRS2 mRNA levels were analyzed in kidney tissues extracted from c-Maf $^{flox/flox}$ and c-Maf ATAM mice using qPCR (n = 12 per group). (C) c-Maf expression around the exocrine cells, such as the macrophages and interstitial area. (D) No morphological changes in the pancreas and (E) no significant difference in amylase levels in the serum under the feeding conditions in c-Maf ATAM mice compared with those in c-Maf $^{flox/flox}$ mice on TAM(10d). (E) Serum Amylase levels did not significantly differ between the two groups. (F) c-Maf expression around the hepatic cells, such as sinusoidal cells and macrophages. (G) No morphological changes in the liver and no significant difference in (H) ALT and (I) AST levels in the serum on TAM(10d). (c-Maf $^{flox/flox}$, n = 4; c-Maf ATAM , n = 5). (J) c-Maf expression and (K) no morphological changes in the small intestine. [C, D, F, G, J, K: n = 4 per group. E, H, I: c-Maf $^{flox/flox}$, n = 4; c-Maf ATAM , n = 5.] An almost identical metabolic phenotype was documented in c-Maf $^{flox/flox}$ and c-Maf ATAM kidneys. (L) Serum basic amino acid, (M) Urine Na, (N) Urine IP, (O) Urine K, (P) Urine Ca, (Q) Urine UA, (R) Serum Na and (S) Serum K levels did not significantly differ between the two groups (n = 5 per group). The structures of glomeruli, proximal tubules, and brush border membranes in c-Maf $^{flox/flox}$ and c-Maf $^{flox/flox}$, n = 7; c-Maf $^{flox/flox}$, n = 5. M, N, O: n = 5. Q: n = 4. P, R, S: n = 5]. (T) Serum creatinine and (U) serum UN levels did not differ significantly between the two groups (n = 5 per group). The structures of glomeruli, proximal tubules, and brush border memb




Supplemental Figure 2. RNA-seq analysis of the relationship between c-Maf and renal features. (A) Heatmap of claster2 expression, which clearly differed between c-Maf and c-Maf and



Supplemental Figure 3. qPCR results showing a significant decrease in *c-Maf* expression, comparable *Glut1* expression, and an increase in *Sglt1* expression in *c-Maf* ATAM mice compared to those in *c-Maf* $^{flox/flox}$ mice. The renal mRNA levels of (A) c-Maf were significantly lower, (B) Glut1 levels did not change in both groups, and (C) Sglt1 was upregulated to compensate for reduced Sglt2 in c-Maf ATAM compared to c-Maf $^{flox/flox}$ group at TAM(10d). [A, B,C: n=12 per group]. Supplemental Figure 3A—C were presented as the mean and the standard error of the mean (SEM). To assess whether differences between c-Maf $^{flox/flox}$ mice were statistically significant, a minimum of three biological replicates were analyzed using Welch's t test, and a P-value < 0.05 was considered significant. NS: Not Significant, and ***P < 0.001. White circles- c-Maf $^{flox/flox}$ groups, and black circles- c-Maf ATAM groups.



Supplemental Figure 4. Schedule of streptozotocin and tamoxifen administration, detection of c-Maf expression and localization, and body weight, food intake, urinary glucose levels, and blood pressure in c-Maf ATAM and c-Maf $^{flox/flox}$ mice under diabetic and/or non-diabetic conditions. (A) S, streptozotocin (STZ); T, tamoxifen (TAM); IPGTT, intraperitoneal glucose tolerance test. Numbers in parentheses indicate the number of weeks after STZ or TAM administration. Under diabetic conditions, (B) c-Maf gene expression was significantly lower in the kidneys of c-Maf $^{flox/flox}$ mice on STZ(7w) TAM(3w) compared to TAM(8w) without STZ. There was no change in c-Maf localization between these groups on (C) TAM(8w) without STZ or (D) STZ(12w) TAM(8w). (E) Sght2 and (F) Glut2 gene expression was significantly lower in the kidneys of c-Maf $^{flox/flox}$ mice on STZ(7w) TAM(3w) compared to TAM(8w) without STZ. [B, E, F: n = 3 on TAM(8w) without STZ; n = 4 on STZ(7w) TAM(3w). C, D: n = 3 per group.] (G) Body weight did not significantly differ between the groups on STZ(4w) TAM(6w) compared to control mice (c-Maf $^{flox/flox}$, n = 5; c-Maf $^{flox/flox}$, n = 6). (H) Food intake did not significantly differ between the groups on STZ(9w) TAM(5w) (c-Maf $^{flox/flox}$, n = 7; c-Maf dTAM , n = 6). (H) Food intake did not significantly differ between the groups on STZ(9w) TAM(8w) (c-Maf $^{flox/flox}$, n = 7; c-Maf dTAM , n = 5). (I) Urinary glucose levels were higher in c-Maf dTAM mice than in control mice on STZ(12w) TAM(8w) (c-Maf $^{flox/flox}$, n = 7; c-Maf dTAM , n = 7). (J) Blood pressure was lower in c-Maf dTAM mice than in control mice (c-Maf $^{flox/flox}$ on TAM(3w) without STZ and STZ(7w) TAM(3w), n = 7; c-Maf dTAM on STZ(7w) TAM(3w), n = 4). Scale bars: 100 µm. Supplemental Figure 4B, E-J were presented as the mean and the standard error of the mean (SEM). To assess whether differences between c-Maf dTAM



Supplemental Table 1. Primer sequences for ChIP assays

Gene	Forward/reverse primer sequence	
c-Maf	Forward	5' -CTGCCGCTTCAAGAGGGTGCAGC-3'
	Reverse	5' -TCGCGTTCACACTCACATG-3'
Sglt2	Forward	5' -CCCAGGAAGGAGTGCTCTTG-3'
	Reverse	5' -GACAAGTCCCCCAGGTCTCA-3'
Sglt2	Forward	5' -GGTCACCAGGCAAGTTAGGC-3'
(negative control)	Reverse	5' -CCCCAGACTGCACCTCCTTA-3'
Glut2	Forward	5' -TGGGGTAAAGGGTGTATTGATTG-3'
	Reverse	5' -TGGAATTGTCCTCTTAATCCAGGT-3'
Glut2	Forward	5' -TCGTTAGGAATGAGGTGACACCA-3'
(negative control)	Reverse	5' -CAGGAAAATGAAAACCCCACA-3'

Supplemental Table 2. Primer sequences for dual luciferase assays and site-directed mutagenesis

Gene	Forward/reverse primer sequence		
	Forwar	5' -ATATGGTACCACCAAATAAAATCTGAGCATGGA-	
Sglt2	d	3'	
(transformation)	Revers	5' -ATATCTCGAGGATTAATGGTTACCTCAGGAGCA-	
	e	3'	
	Forwar	5' -GGTACCACCAAATAAAATCTGAGCATGGA-3'	
Sglt2	d		
(sequence)	Revers	5' -CTCGAGGATTAATGGTTACCTCAGGAGCA-3'	
	e		
	Forwar	5' -AGGATTCAGCTAAATAAAGCTGGAGAA-3'	
Sglt2	d		
(mutagenesis)	Revers	5' -GATCTATCAAGGCCGAAGGCTG-3'	
	Forwar		
Glut2	d	5' -ATATACAGAGCCCACAGAACTAATTTTC-3'	
(transformation)	Revers		
(uunsionnuuron)	e	5' -ATATGAATTTGCTTAGTAGCCAAAAGGA-3'	
	Forwar		
Glut2	d	5' -CACTAAAATGCTGTGATTCCAACC-3'	
(sequence)	Revers		
	e	5' -ATATGAATTTGCTTAGTAGCCAAAAGGA-3'	

Glut2	Forwar	5/ TOCTATEGATEGA CATEGA CTA CA CCA 2/
(mutagenesis)	d	5' -TCCTATTCATCCACATTCAGTACAGGA-3'
(managemesis)		
	Revers	5/ CAGGAGGAGAGTGCTGAGTGTA 2/
	e	5' - GACCAGCCAGAGTGCTCACTCTA-3'

Supplemental Table 3. Primer sequences for qPCR

Gene	Forward/reverse primer sequence		
Hprt	Forward	5' -TTGTTGTTGGATATGCCCTTGACTA-3'	
	Reverse	5' -AGGCAGATGGCCACAGGACTA-3'	
IRS1	Forward	5' -GTTGAGTTGGGCAGAATAGGC-3'	
	Reverse	5' -GGTATCCACATAGCTTTGACGAG-3'	
IRS2	Forward	5' -CAGTGGGGGCGAACTCTATG-3'	
IKS2	Reverse	5' -CAGGCGTGGTTAGGGAATAAG-3'	
Lrp2 (Megalin)	Forward	5' -CAGTGGATTGGGTAGCAGGA-3'	
	Reverse	5' -GCTTGGGGTCAACAACGATA-3'	
Cubn (Cubilin)	Forward	5' -TCATTGGCCTCAGACATTCC-3'	
	Reverse	5' -CCCAGACCTTCACAAAGCTG-3'	
Sglt2	Forward	5' -GCAACATCGGCAGCGGTCAT-3'	
	Reverse	5' -GCGGAGGTACTGAGGCATTGTG-3'	
Glut2	Forward	5' -TCTTCACGGCTGTCTCTGTG-3'	
	Reverse	5' -AATCATCCCGGTTAGGAACA-3'	
c-Maf	Forward	5' -GGTGGATTGTAGAGGGGAGAG-3'	
	Reverse	5' -GTTACGGGGGAATTCAGGTT-3'	
Glut1	Forward	5' -ATGGATCCCAGCAGCAAG-3'	
	Reverse	5' -CCAGTGTTATAGCCGAACTGC-3'	
Sglt1	Forward	5' -CACCATCTTGATCATCTCCTT-3'	
	Reverse	5' -TGCGTAGACTCCAACACAAAC-3'	

	Forward	5' -AGAGACCTTGGTGGAGTGT-3'
HNF1α	Reverse	5' -GGCAAACCAGTTGTAGACACGC-3'